Sort
8,912 grants matching “sars cov 2”
Intersection of HIV-1 Tat and SARS-CoV-2 S1 on neuroinflammation
$1,971,308Xuesong Chen · University Of North Dakota · RF1 · FY2023 · MH
Center for Solutions for ME/CFS
$1,968,142W. Ian Lipkin · Columbia University Health Sciences · U54 · FY2024 · NS
Wastewater Detection of COVID-19
$1,962,927Jeff Wenzel · Missouri State Dept/ Health & Senior Srv · U01 · FY2022 · DA
Characterization of the cellular and molecular bases of inborn errors of immunity
$1,953,817Luigi Notarangelo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Development testing of nucleic acid-based vaccine for HIV other indications
$1,950,208Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Identification of targets of CD4 and CD8 T cell reactivity conserved across Sarbecoviruses and recognized across different animal species
$1,946,055Alba Grifoni · Washington University · P01 · FY2022 · AI
The Southwest National Primate Research Center
$1,943,312Larry S. Schlesinger · Texas Biomedical Research Institute · P51 · FY2023 · OD
Immunobiology and therapy of oral mucosal and salivary gland chronic graft-versus-host disease
$1,939,380Jacqueline Mays · National Institute Of Dental & Craniofacial Research · ZIA · FY2024 · DE
Cardiovascular Genomics and Bioinformatics projects
$1,938,718Andrew Johnson · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL
Vasculitis and Translational Medicine
$1,937,697Peter Grayson · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2021 · AR
Surveillance for Vaccine Preventable Disease in Children
$1,936,000Julie Anne Boom · Baylor College Of Medicine · U01 · FY2022 · IP
IP21-002, US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,936,000Rangaraj Selvarangan · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2022 · IP
IP21-002, Enhanced Surveillance Network for Enteric and Respiratory Viruses in Children: Assessing Disease Burden, Natural History, and Vaccine Effectiveness
$1,936,000Geoffrey Alan Weinberg · University Of Rochester · U01 · FY2022 · IP
Enhanced Surveillance for New Vaccine Preventable Diseases
$1,936,000Natasha Bassam Halasa · Vanderbilt University Medical Center · U01 · FY2022 · IP
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children
$1,935,998Mary A Staat · Cincinnati Childrens Hosp Med Ctr · U01 · FY2022 · IP
Structure-guided immunogens to elicit pan-coronavirus B cell responses
$1,934,136Aaron Gregory Schmidt · Washington University · P01 · FY2022 · AI
IP21-002, Enhanced Surveillance to Assess Vaccine Preventable Enteric and Respiratory Virus Illnesses
$1,933,284Janet A Englund · Seattle Children'S Hospital · U01 · FY2022 · IP
Emerging respiratory viruses - pathogenesis and countermeasures
$1,927,539Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
IP21-002, New Vaccine Surveillance Network
$1,924,241John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2022 · IP
Protein Structure
$1,923,299Alexander Wlodawer · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Eosinophils and Eosinophil Activation in the Pathogenesis of Human Disease
$1,922,731Amy Klion · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Tulane University COVID Antibody and Immunity Network (TUCAIN)
$1,920,358James E Robinson · Tulane University Of Louisiana · U54 · FY2022 · CA
COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2
$1,912,140Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
Developing Vaccine Candidates for the SARS Coronavirus
$1,907,553Ralph S Baric · Univ Of North Carolina Chapel Hill · P01 · FY2009 · AI
Project 3: Nucleoside-modified mRNA-LNP vaccine platform
$1,904,954Barton F Haynes · Duke University · P01 · FY2021 · AI